These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30132234)

  • 1. Overview of this issue: pharmacovigilance, what is new?
    Martin LG; Hanssens Y; Paudyal V
    Int J Clin Pharm; 2018 Aug; 40(4):737-739. PubMed ID: 30132234
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance: Basic concepts and an overview of the system in Oman.
    Jose J; Al Rubaie MH; Al Ramimmy H; Varughese SS
    Sultan Qaboos Univ Med J; 2021 May; 21(2):e161-e163. PubMed ID: 34221460
    [No Abstract]   [Full Text] [Related]  

  • 4. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.
    de Vries ST; Denig P; Ekhart C; Burgers JS; Kleefstra N; Mol PGM; van Puijenbroek EP
    Br J Clin Pharmacol; 2019 Jul; 85(7):1507-1515. PubMed ID: 30941789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting adverse drug reactions: contribution, knowledge and perception of German pharmacy professionals.
    Laven A; Schmitz K; Franzen WH
    Int J Clin Pharm; 2018 Aug; 40(4):842-851. PubMed ID: 29909562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance implemented by patients: A necessity in the 21st century.
    Lafond J
    Therapie; 2016 Apr; 71(2):245-7. PubMed ID: 27080846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An historical overview over Pharmacovigilance.
    Fornasier G; Francescon S; Leone R; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):744-747. PubMed ID: 29948743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions reporting culture in Pharmacovigilance Programme of India.
    Kalaiselvan V; Prasad T; Bisht A; Singh S; Singh GN
    Indian J Med Res; 2014 Oct; 140(4):563-4. PubMed ID: 25488454
    [No Abstract]   [Full Text] [Related]  

  • 11. Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar.
    Al Hail M; Elkassem W; Hamad A; Abdulrouf P; Thomas B; Stewart D
    Int J Clin Pharm; 2018 Aug; 40(4):769-774. PubMed ID: 29616393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database.
    Kaguelidou F; Beau-Salinas F; Jonville-Bera AP; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2016 Oct; 82(4):1058-68. PubMed ID: 27276109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center].
    Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T
    Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Importance and specificity of pharmacovigilance in the pediatric population].
    Rodieux F; Ing-Lorenzini K; Rollason V
    Rev Med Suisse; 2019 Apr; 15(645):743-747. PubMed ID: 30942973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning on adverse drug reactions for pharmacovigilance.
    Lee CY; Chen YP
    Drug Discov Today; 2019 Jul; 24(7):1332-1343. PubMed ID: 30876845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indian College of Physicians (ICP) Position Statement on Pharmacovigilance.
    Dhamija P; Kalra S; Sharma PK; Kalaiselvan V; Muruganathan A; Balhara YPS; Badani R; Bantwal G; Das AK; Dhorepatil B; Ghosh S; Jeloka T; Khandelwal D; Nadkar MY; Patnaik KP; Saboo B; Sahay M; Sahay R; Tiwaskar M; Unnikrishnan AG
    J Assoc Physicians India; 2017 Mar; 65(3):63-66. PubMed ID: 28462545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system].
    Aguirre C; García M
    Med Clin (Barc); 2016 Nov; 147(10):461-464. PubMed ID: 27450163
    [No Abstract]   [Full Text] [Related]  

  • 18. Measuring the impact of pharmacovigilance activities, challenging but important.
    van Hunsel F; Gardarsdottir H; de Boer A; Kant A
    Br J Clin Pharmacol; 2019 Oct; 85(10):2235-2237. PubMed ID: 31368147
    [No Abstract]   [Full Text] [Related]  

  • 19. The history of pharmacovigilance.
    Caron J; Rochoy M; Gaboriau L; Gautier S
    Therapie; 2016 Apr; 71(2):129-34. PubMed ID: 27080830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.